

Cardiac transplantation is still the method of choice in the treatment of patients with severe heart failure

Jerzy Korewicki

Institute of Cardiology, Warszawa, Poland

Abstract

A significant progress in the treatment of heart failure occurred during the last 20 years. These advances were associated with the introduction and subsequent widespread use of angiotensin-converting enzyme inhibitors and beta blockers, but also with progress in device therapy and cardiac surgery. Overall, prognosis in patients with severe heart failure is similar to outcomes reported in multicenter randomized clinical trials, such as CONSENSUS, CIBIS II, MERIT-HF, and COPERNICUS. In 2003–2007, a registry of patients with severe heart failure was established in Poland (POLKARD-HF) that included all patients initially considered candidates for heart transplantation (HTX). Mean duration of follow-up was 601 days (range 1–1462 days). One-year mortality (defined as death or super-urgent HTX) was 20% and differed from data presented by Stewart (2001). In addition, patient survival in the POLKARD-HF registry depending on the New York Heart Association (NYHA) class changed significantly in comparison to outcomes reported in the late 1980s. However, one-year mortality among NYHA class IV patients is still high and exceeds 50%. As reported in the POLKARD-HF registry, one-year risk of death among patient who underwent elective HTX was about 20%, and 3-year risk was about 22%, significantly different from the risk of death among medically treated patients with heart failure. These results are similar to other European data and warrant reconsideration of appropriateness of HTX in elective patients (UNOS 2 status). Undoubtedly, NYHA class IV patients are candidates for HTX and should remain under specialist care in cardiac transplantation centers, and HTX should be performed in this group when indications for this procedure become urgent (UNOS 1 and 1a status).

A specialized system of care for patients with severe heart failure should be created in Poland, particularly for patients referred for HTX. There is also an urgent need to introduce modern systems of mechanical cardiac support (left ventricular assist devices, LVAD) that would allow precise determination of indications and contraindications to HTX and create opportunities for long-term treatment. (Cardiol J 2009; 16, 6: 493–499)

Key words: severe heart failure, cardiac transplantation, prognosis

In 2001, Stewart et al. [1] noted that the 5-year survival in patients with heart failure was worse than in patients with most cancers. One-year survival with heart failure was less than 60%, and 4-year survival was about 35%, thus heart failure was dubbed “more malignant than cancer”.

During the last 20 years, a significant progress in the treatment of heart failure occurred, related not only to pharmacotherapy, but also to device therapy and invasive treatment [2–6]. These advances in therapy resulted in improved prognosis and quality of life of patients with heart failure, including those with severe heart failure. In patients with the New York Heart Association (NYHA) class IV patients who participated in the CONSENSUS study, treatment with enalapril was associated with a relative reduction of the risk of death by 40% at 6 months and by 31% at one year of treatment compared to the control group [4, 6]. Another advance in pharmacotherapy of heart failure was the introduction of beta₁-adrenergic receptor antagonists (beta-blockers). A metaanalysis of CIBIS II, MERIT HF, and COPERNICUS studies showed a relative reduction of the risk of death by 33% in NYHA class III patients and 31% in NYHA class IV patients [5, 7, 8]. Based on these studies, it may be theoretically assumed that one-year mortality in patients with severe heart failure receiving conventional treatment (i.e. with digitalis and diuretics) would be 52%. Treatment with a angiotensin-converting enzyme (ACE) inhibitor should lower this mortality rate to 36%, and additional use of an aldosterone antagonist would result in lowering one-year mortality to 18%. Full treatment according to current guidelines should lower one-year mortality among patients with severe heart failure (NYHA class III–IV) to about 12% [9].

These estimations have been confirmed in numerous contemporary epidemiological studies. In the United States, one-year mortality among patients with severe heart failure in 1994–1997 was about 20%, and 3-year mortality was about 67%. In 1999–2001, corresponding mortality rates were 12% and 79%, respectively. The effects of treatment depend on the age of patients. Prognosis in patients aged less than 75 years is similar to that found in the above mentioned studies from the United States but it is significantly worse among patients over 75 years of age. One-year mortality among patients aged more than 75 years is about 37%, and 3-year mortality is about 60% [10–12].

Further considerations, as related to the main topic of this paper, will be restricted to patients with severe heart failure under 65 years of age. This is

the population of patients primarily considered for heart transplantation (HTX).

Outcomes after HTX improved substantially with the introduction of modern immunosuppressive treatment, mainly with calcineurin inhibitors such as cyclosporine. Data from the International Society for Heart and Lung Transplantation (ISHLT) registry show that in 1993–2000, survival at 1, 3, 5, and 10 years was about 85%, 75%, 70%, and 50%, respectively [13, 14].

Potential candidates to HTX (based on [15]) are patients under 65 years of age with heart failure who fulfill the following criteria despite optimal treatment:

- NYHA class III–IV heart failure symptoms;
 - episodes of hypervolemia or reduced cardiac output at rest;
 - ejection fraction reduced below 30%;
 - Doppler evidence of impaired left ventricular diastolic filling;
 - high left ventricular end-diastolic pressure or mean pulmonary capillary wedge pressure > 19 mm Hg and mean right atrial pressure > 12 mm Hg;
 - elevated level of N-terminal propeptide of the brain natriuretic peptide (NT-proBNP) (> 2000 pg/mL);
 - frequent hospitalizations due to heart failure during the last 6 months, requiring administration of catecholamines;
- and in whom functional studies show:
- inability to exercise (NYHA class IV);
 - 6-minute walking distance of less than 300 m;
 - maximal oxygen uptake (VO₂max) of less than 12–14 mL/kg/min.

Extrapolating data from the ISHLT registry in 1999–2001, approximately 850 patients in Poland should qualify for HTX during 3 years (in 2003–2005, in fact 335 patients actually qualified), including 50% of patients qualifying for an urgent transplantation (about 20% patients in Poland).

The Poltransplant criteria for an urgent HTX are as follows:

- mechanical cardiac support due to acute circulatory decompensation;
- continuous mechanical ventilation;
- severe refractory arrhythmia;
- acute heart failure within 7 days after HTX.

Poltransplant HTX qualifying criteria are more liberal than the UNOS or Eurotransplant criteria but do not account data regarding prognosis in these patients. This is an important issue due to a different system of care for patients qualifying for HTX in Poland compared to other European countries

and the United States. In Poland, patients qualifying for an urgent HTX who present to transplantation centers are usually critically ill. In these circumstances, precise determination of indications and contraindications for HTX is sometimes difficult. This is probably the main reason of worse HTX outcomes in these patients compared to the United States and Western Europe. Systems of mechanical cardiac support available in Poland that might improve diagnostic work-up and prognosis in patients qualifying for an urgent HTX may be used only for a relatively brief period (about 2–3 months) and only in hospitalized patients. A larger group (about 80% of patients in Poland) that is very heterogeneous in terms of clinical characteristics and prognosis includes patients qualifying for an elective HTX.

In 2003–2007, a registry of patients with severe heart failure initially considered as candidates for HTX (POLKARD-HF) was set up in Poland using a grant from the Polish Ministry of Health [16]. The main objective of this program was to evaluate prognosis in patients with severe heart failure prior to HTX and also after HTX in patients who eventually underwent transplantation. An additional goal was to identify risk factors for death or an urgent HTX. Results of this registry may be used to extend previous data and define more precise criteria allowing qualification for HTX. Overall, 983 patients were included in the registry in four centers performing HTX in Poland in 2003–2007 (Table 1).

Most of these patients ($n = 658$) qualified for HTX and during the period covered by the registry, transplantation was actually performed in 325 patients. Patients included in the registry were young (mean age 49 ± 11 years), had advanced heart failure with ejection fraction of $21.6 \pm 8\%$, low systemic blood pressure (102 ± 15 mm Hg), and showed evidence of moderate pulmonary hypertension. Laboratory tests showed elevated levels of high-sensitivity C-reactive protein (hsCRP) (mean 3.0 mg/L, range 0.03 – 347.0), and NT-proBNP (mean 2294 pg/mL, range 28 – 46128), while mean sodium level was 136 ± 4 mEq/L. The mean duration of follow-up was 601 days (range 1 – 1462) (Fig. 1).

Survival of patients with severe heart failure or undergoing an urgent HTX was about 80% at one year and 67% at 3 years of follow-up, and thus was substantially higher than among patients with heart failure included in the study by Stewart et al. [1] (56% and 34%, respectively) (Fig. 2).

Analysis of outcomes in patients with heart failure depending on the NYHA functional class also showed significant improvement compared to the

Table 1. Characteristics of patients with severe heart failure included in the POLKARD-HF registry in 2003–2007 [16].

Variable	N	Mean \pm SD *Median [Min–Max]
Age (years)	983	49.38 \pm 11.245
Body mass [kg]	982	77.9 \pm 15.42
Height [cm]	980	172.8 \pm 9.71
BMI [kg/m ²]	979	25.982 \pm 4.5004
EF (%)	978	21.6 \pm 8.13
LVEDD [mm]	953	71.93 \pm 10.472
LVESD [mm]	905	60.30 \pm 13.217
HR [bpm]	962	78.3 \pm 15.80
Systolic BP [mm Hg]	975	102.6 \pm 14.97
Diastolic BP [mm Hg]	975	67.0 \pm 11.12
PASP [mm Hg]	629	44.9 \pm 17.41
Mean PCWP [mm Hg]	695	20.8 \pm 9.41
CI [L/min/m ²]	530	1.95 \pm 0.854
PVR [Wood Units]	64	3.13 \pm 2.392
PG [mm Hg]	654	10.61 \pm 6.677
hsCRP [mg/L]*	679	3.00 [0.03–347.00]
NT-proBNP [pg/mL]*	694	2294.5 [28.0–46128.0]
VO ₂ max [mL/kg/l]	687	13.05 \pm 4.345
HFSS	952	7.7 \pm 0.98
Na [mEq/L]	973	136.4 \pm 4.41

BMI — body mass index; EF — ejection fraction; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; HR — heart rate; BP — blood pressure; PASP — pulmonary artery systolic pressure; PCWP — pulmonary capillary wedge pressure; CI — cardiac index; PVR — pulmonary vascular resistance; PG — pulmonary gradient; hsCRP — high sensitivity C-reactive protein; NT-proBNP — N-terminal propeptide of the brain natriuretic peptide; VO₂max — maximal oxygen uptake; HFSS — Heart Failure Survival Score; Na — sodium

studies performed in the late 80s [12–14, 16, 17]. Of note, prognosis among NYHA class IV patients is still very poor, as one-year mortality in this group (defined as death or a very urgent HTX) was 50% (Table 2).

Based on Kaplan-Meier survival analysis, the following significant prognostic factors were identified: pulmonary artery systolic pressure, mean pulmonary capillary wedge pressure, left ventricular ejection fraction, NYHA functional class, low systemic blood pressure, hsCRP level, NT-proBNP level, body mass index, sodium level, and Heart Failure Survival Score (HFSS) proposed by Aaronson et al. (Table 3) [17, 18].

In multivariate analysis, after removal of NYHA functional class and HFSS as dependent variables, the following variables remained independent risk factors for death or a very urgent HTX: NT-proBNP level ≥ 4302 pg/mL and sodium level ≤ 135 mEq/L. Of note, HFSS calculated using the Aaronson formula, incorporating clinical, functional, and bio-




Figure 1. Probability of survival of patients with heart failure [1, 16].




Figure 2. Probability of survival of patients with heart failure depending on the New York Heart Association (NYHA) functional class (— Kaplan-Meier curves for patients with heart failure included in the POLKARD-HF registry, Kaplan-Meier curves for patients with heart failure based on data from Massie B et al. Circulation, 1987; 75: 11–19).

Table 2. Risk factors for death of an urgent heart transplantation (values are upper or lower limits of terciles determined as statistically significant in the Kaplan-Meier analysis); POLKARD-HF [16].

YES	NO
Pulmonary artery systolic pressure \geq 50 mm Hg	Pulmonary vascular resistance
Pulmonary capillary wedge pressure \geq 25 mm Hg	Pulmonary gradient
Left ventricular ejection fraction \leq 17%	Cardiac index
NYHA functional class IV	VO ₂ max
Systolic blood pressure \leq 90 mm Hg	Diastolic blood pressure
hsCRP \geq 6.5 mg/L	Etiology of heart failure
NT-proBNP \geq 4302 pg/mL	Sex
HFSS \leq 7.19	
Sodium \leq 135 mEq/L	
Body mass index \leq 23.8 kg/m ²	

NYHA — New York Heart Association; hsCRP — high sensitivity C-reactive protein; NT-proBNP — N-terminal propeptide of the brain natriuretic peptide; HFSS — Heart Failure Survival Score; VO₂max — maximal oxygen uptake.

Table 3. Variables included in the Heart Failure Survival Score (HFSS) proposed by Aaronson et al. [18, 26].

Ischemic heart disease (yes = 1, no = 0)	(..... x 0.6931) = +
Intraventricular conduction disturbances (yes = 1, no = 0)	(..... x 0.6083) = +
Ejection fraction (%)	(..... x 0.0464) = +
Heart rate [bpm]	(..... x 0.0221) = +
Sodium level [mEq/L]	(..... x - 0.0470) = +
Mean arterial pressure [mm Hg]	(..... x - 0.0255) = +
Maximal oxygen uptake (VO ₂ max)	(..... x - 0.546) = +
	HFSS =

chemical parameters, is routinely evaluated in patients with heart failure and has a very high prognostic importance. Values of 5.5–7.19 are associated with a high risk of death, values of 7.2–9.09 with a moderate risk, and values of 8.1–10.49 with a low risk of death. In the POLKARD-HF registry of patients with severe heart failure, mean HFSS was 7.7 ± 0.98 , and in the highest risk group (with one-year mortality of 50%) it was ≤ 7.19 [18–22].

Patients entering the registry were generally treated according to the current guidelines, with 90–100% of patients receiving beta₁-adrenergic receptor antagonists, ACE inhibitors and diuretics, and about 80% of patients treated with aldosterone antagonists. However, the doses used were much lower than those recommended in the current guidelines, as the doses of standard drugs, except diuretics, were only about 25% of the recommended dosage on admission (and entry into the registry), and about 50% at hospital discharge (unpublished results based on patients entered into the registry in the Institute of Cardiology).

As most patients were not initially receiving adequate treatment, final evaluation of indications for HTX was done, if possible, at 3 months after the entry into the registry, thus allowing time for treatment optimization.

Patients scheduled for elective HTX remained under the ambulatory care until transplantation in the centers participating in the registry. Patients at higher risk of HTX, mainly with reversible (reactive) pulmonary hypertension, were evaluated every 3 months, and the remaining patients were evaluated every 6 months. Patients with heart failure who were considered potential candidates but were not scheduled for elective HTX, also remained under the ambulatory care in the centers participating in the registry.

Three-year outcomes in patients who underwent elective HTX differed from outcomes in medically treated patients, mainly due to deaths occurring in the first days or weeks after HTX (Fig. 3).

Our experience and data collected in other centers suggest that it is questionable whether HTX should be performed at all in patients scheduled for




Figure 3. Prognosis in patients with severe heart failure; a — heart transplantation, elective qualification; b — drug therapy, elective qualification; c — drug therapy, no indications for heart transplantation; POLKARD-HF [16].

an elective procedure, in whom one-year mortality does not exceed 20%. Based on the data available in the literature and the results of the registry, one-year mortality in patients with severe heart failure (excluding patients with indications for an urgent HTX) is 9.7–13.5%. Thus, it seems that the potential benefit of HTX in these patients, realized after 5–10 years, does not warrant the decision to proceed with the transplantation. There is an urgent need to verify indications for HTX based not only on the patient clinical condition [11, 12, 23–26] but also using additional prognostic factors such as HFSS and NT-proBNP level [11, 18, 21, 22]. It also seems that patients scheduled for elective HTX who require recurrent hospitalizations related to cardiac decompensation and need support with inotropic drugs despite apparently optimal treatment, should be considered candidates for an urgent HTX. There is also an urgent need to establish a system of specialist care for patients with severe heart failure, preferably in centers performing HTX and able to use modern systems of mechanical cardiac support.

Conclusions

1. Modern drug therapy as recommended in the current guidelines has resulted in significantly improved outcomes in patients with severe heart failure.
2. Cardiac transplantation is still the method of choice in the treatment of patients with severe heart failure qualifying for an urgent HTX (NYHA class IV).

3. Patients scheduled for elective HTX in whom low HFSS value or high NT-proBNP level is demonstrated, or who require recurrent hospitalizations due to cardiac decompensation despite apparently optimal treatment, should undergo an urgent HTX.
4. Top priorities should include immediate implementation of modern systems of mechanical cardiac support and establishing highly specialized centers caring for patients with severe heart failure.

Acknowledgements

The author appreciate help of Piotr Jędrusik with preparation of the authorized English version of the manuscript.

The author does not report any conflict of interest regarding this work.

Opinions presented by the author may sometimes deviate from the official positions as stated in the guidelines.

POLKARD was realized as grant of Polish Ministry of Health 1304/IK-AG-K-283/03, Clinicaltrials.gov.no.NCT00690157.

References

1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. *Eur J Heart Fail*, 2001; 3: 315–322.
2. Klotz S, Loeher A, Drees G, Scheld HH. Surgical therapy of end-stage heart failure. *State of the art 2006. Herz*, 2006; 31: 445–454.
3. Allen LA, Felker GM. Advances in the surgical treatment of heart failure. *Curr Opin Cardiol*, 2008; 23: 249–253.
4. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group. *N Engl J Med*, 1987; 4: 1429–1435.
5. Domanski MJ, Krause-Steinrauf H, Massie BM et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. *J Card Fail*, 2003; 9: 354–363.
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*, 1991; 1: 293–302.
7. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation*, 1994; 90: 1765–1773.
8. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med*, 1996; 23: 1349–1355.
9. Cleland JGF, Louis A, Witte K. Pharmacoeconomics in heart failure: Impact of drug and non-drug based treatment. *Eur Heart J*, 2001; 3 (suppl. G): G25–G32.

10. Cleland JGF, Khand A, Clark AC. The heart failure epidemiology: Exactly how big is it? *Eur Heart J*, 2001; 22: 623–665.
11. Gardner R, Mc Donagh T, Mac D et al. Who needs a heart transplant? *Eur Heart J*, 2006; 27: 770–772.
12. Butler J, Khadim G, Paul KM et al. Selection of patients for heart transplantation in the current era of heart failure therapy. *J Am Coll Cardiol*, 2004; 43: 787–793.
13. Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report — 2005. *J Heart Lung Transplant*, 2005; 24: 945–955.
14. Almenar-Bonet L. Spanish Working Groups on Heart Transplantation. Spanish heart transplantation registry. 18th official report of the Spanish Society of Cardiology working group on heart failure, heart transplantation and associated therapies (1984–2006). *Rev Esp Cardiol*, 2007; 60: 1177–1187.
15. Metra M, Ponikowski P, Dickstein K et al. Advanced chronic heart failure: a position statement from the Study Group on advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*, 2007; 9: 689–694.
16. Korewicki J, Browarek A, Zembala M et al. Ogólnopolski rejestr chorych z ciężką niewydolnością serca, zakwalifikowanych do przeszczepu serca — POLKARD-HF 2003–2007. *Folia Cardiologica Excerpta*, 2008; 3: 403–421.
17. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. *Am J Cardiol*, 1983; 1: 831–836.
18. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. *Circulation*, 1997; 17: 2660–2667.
19. Koelling TM, Joseph S., Aaronson KD. Heart failure survival score continues to predict clinical outcome in patients with heart failure receiving beta-blockers. *J Heart Lung Transplant*, 2004; 23: 1414–1422.
20. Van den Broek SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hillege H, Lie KI. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol*, 1992; 1: 359–363.
21. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. *Eur Heart J*, 2003; 24: 1735–1743.
22. Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: Linear correlation with exercise tolerance. *J Heart Lung Transplant*, 2007; 26: 516–521.
23. Caderiraz M, Bayern MP, Deng MC. Cardiac transplantation: any role left? *Heart Fail Clin*, 2007; 3: 321–347.
24. Deng MC, Smith JM, Young JB. Proposition: The benefit of cardiac transplantation in stable outpatients with heart failure should be tested in a randomized trial. *J Heart Lung Transplant*, 2003; 22: 113–117.
25. Jimenez J, Edwards LB, Higgins R et al. Should stable UNOS status 2 patients be transplanted? *J Heart Lung Transplant*, 2005; 24: 178–183.
26. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. *Am J Cardiol*, 2003; 1: 1350–1354.